



(51) International Patent Classification:

C07D 217/16 (2006.01) *A61P 25/16* (2006.01)
A61K 31/472 (2006.01) *A61P 25/18* (2006.01)

(21) International Application Number:

PCT/US2014/039494

(22) International Filing Date:

27 May 2014 (27.05.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/828,740 30 May 2013 (30.05.2013) US
61/905,329 18 November 2013 (18.11.2013) US

(71) Applicant: **ELI LILLY AND COMPANY** [US/US];
Lilly Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors: **BEADLE, Christopher David**; c/o Eli Lilly and Company, P. O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **COATES, David Andrew**; c/o Eli Lilly and Company, P. O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **HAO, Junliang**; c/o Eli Lilly and Company, P. O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **KRUSHINSKI JR., Joseph Herman**; c/o Eli Lilly and Company, P. O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **REINHARD, Matthew Robert**; c/o Eli

Lilly and Company, P. O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **SCHAUS, John Mehnert**; c/o Eli Lilly and Company, P. O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **WOLFANGEL, Craig Daniel**; c/o Eli Lilly and Company, P. O. Box 6288, Indianapolis, Indiana 46206-6288 (US).


(74) Agents: **WINTER, Mark A.** et al.; Eli Lilly and Company, P. O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

[Continued on next page]

(54) Title: 3,4-DIHYDROISOQUINOLIN-2(1H)-YL COMPOUNDS



(57) Abstract: The invention provides certain 3,4-dihydroisoquinolin-2(1H)-yl compounds, particularly compounds of formula (I), and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula (I) to treat cognitive impairment associated with Parkinson's disease or schizophrenia.



EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

— *as to the applicant's entitlement to claim the priority of
the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii))*